Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Developments in Engineered T Cells for Type 1 Diabetes

AZoLifeSciences speaks to Professor David J. Rawlings from the Seattle children's hospital about recent developments in engineered T cells for type 1 diabetes.

23 Jun 2020

Deleting a key gene to create an immune cell with stronger anti-tumor activity

Using induced pluripotent stem cells (iPSCs) and deleting a key gene, researchers at University of California San Diego School of Medicine have created natural killer cells -- a type of immune cell -- with measurably stronger activity against a form of leukemia, both in vivo and in vitro.

From UC San Diego 12 Jun 2020

Researchers identify key gene essential for leukemia stem cells' survival

Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.

4 Jun 2020

A New Tool To Map The Flow Of Info Within Living Cells

How do cells move? Why do they move? Why do some cancer cells move slowly while others move quickly, causing cancerous tumors to become more difficult to treat?

19 May 2020

Mouse model helps track organism’s development, cell by cell

Scientists at the Stem Cell Research program at Boston Children's Hospital and Dana-Farber Cancer Institute/Harvard Medical School have devised a mouse model that lets researchers track every cell in the body, from the embryonic stage until adulthood.

15 May 2020

Treating solid cancers using the formation of natural killer-tumor cell immunological synapse

There are immune cells in our bodies that directly destroy infected or cancer cells - they are called natural killer cells. Recently, a POSTECH research team has developed an integrative cancer therapy using adoptive natural killer cell therapy and chemotherapy.

14 May 2020

Research uncovers a novel mechanism for controlling genes

The genetic information within our cells is what makes humans unique. The cell nucleus has a complex structure that harbors this genetic information.

13 May 2020

Selectively eliminating leukemic and hematopoietic stem cells

Acute myeloid leukemia is an aggressive cancer of the blood-forming system. It affects the hematopoietic stem cells, or blood stem cells, of various white blood cells and of the red blood cells and platelets.

11 May 2020

MSC‐induced Treg population can yield abundant replacement for naturally occurring T-cells

A new study released today in STEM CELLS suggests for the first time that regulatory T-cells (Treg) induced by mesenchymal stromal cells can yield an abundant replacement for naturally occurring T-cells, which are vital in protecting the body from infection.

30 Apr 2020

Immune System Changes Occur Early In Development Of Multiple Myeloma

Before multiple myeloma becomes a malignant disease, the collection of immune system cells and signal carriers amid the tumor cells undergo dramatic shifts.

29 Apr 2020

Researchers use genome-wide CRISPR technology to identify leukemia's weakness

A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse.

From UC San Diego 21 Apr 2020

Study explores the impact of solute carriers on the activity and potency of cytotoxic drugs

At the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, scientists have investigated how solute carriers (SLCs)—a large class of membrane transport proteins—affect the activity and potency of cytotoxic drugs, for example, those used to treat leukemia and other cancers.

10 Mar 2020

A new study finds a potential immunotherapeutic pan-target on cancer cells

In a genome-wide CRISPR-Cas9 screen published in Nature Immunology in January 2020, a group of researchers described a potential universal target on cancer cells.

12 Feb 2020